Company profile: Ironwood Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of pharmaceuticals for gastrointestinal and cardiovascular diseases, including LINZESS (linaclotide) for IBS-C and CIC; and a pipeline of investigational therapies: apraglutide for SBS-IF; CNP-104 for primary biliary cholangitis; and IW-3300, a GC-C agonist for visceral pain conditions such as interstitial cystitis/bladder pain syndrome and endometriosis.
Products and services
- Apraglutide: An investigational-stage, once-weekly treatment for Short Bowel Syndrome with Intestinal Failure (SBS-IF), engineered to increase intestinal absorption of fluids, calories, and nutrients in affected patients
- IW-3300: A proof-of-concept-stage GC-C agonist being developed for visceral pain conditions such as interstitial cystitis/bladder pain syndrome (IC/BPS) and endometriosis
- LINZESS (linaclotide): A prescription-grade medication used to treat IBS-C and CIC by targeting the guanylate cyclase-C (GC-C) enzyme in the intestine
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Ironwood Pharmaceuticals
CinDome Pharma
HQ: United States
Website
- Description: Provider of treatment for the millions of people living with the devastating impact of chronic gastroparesis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CinDome Pharma company profile →
Cinclus Pharma
HQ: Sweden
Website
- Description: Provider of research-based biotech solutions developing small-molecule therapies for gastric acid–related diseases, notably linaprazan glurate for GERD and Helicobacter pylori with improved action over PPIs. Completed Phase II and preparing Phase III for GERD; QIDP designation from the FDA for H. pylori. Based in Basel, Switzerland; main asset X842 studied in Phase I.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cinclus Pharma company profile →
Venaxis
HQ: United States
Website
- Description: Provider of in vitro diagnostics, focused on developing and commercializing a unique multi-biomarker diagnostic; based in Colorado.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Venaxis company profile →
Inventiva
HQ: France
Website
- Description: Provider of oral small molecule therapies in development for fibrosis, lysosomal storage disorders and oncology. Pipeline includes lanifibranor (Phase III for NASH) and odiparcil (Phase IIa for MPS VI), the PanNASH research initiative, partnerships with Sino Biopharm and Hepalys Pharma, and a 240,000-compound library supporting discovery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inventiva company profile →
Meritage Pharma
HQ: United States
Website
- Description: Provider of prescription products for gastrointestinal and atopic diseases, offering budesonide-based therapies, including an oral budesonide suspension and budesonide API used in treatments for pediatric asthma, allergic rhinitis, and Crohn's disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Meritage Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Ironwood Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Ironwood Pharmaceuticals
2.2 - Growth funds investing in similar companies to Ironwood Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Ironwood Pharmaceuticals
4.2 - Public trading comparable groups for Ironwood Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →